Psychiatric disorders newly diagnosed among veterans subsequent to hospitalization for COVID-19

Chen, Jason I.; Hickok, Alex; O’Neill, Allison C.; Niederhausen, Meike; Laliberte, Avery Z.; Govier, Diana J; Edwards, Samuel T.; Gordon, Howard S.; Slatore, Christopher G.; Weaver, Francis M.; Young, Rebecca; Hynes, Denise M.

doi:10.1016/j.psychres.2022.114570

Cited by 6 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies attempting to investigate the association of long COVID with new-onset neuropsychiatric manifestations have mainly used retrospective cohort study designs and data from national health registries (16)(17)(18)(19)(20)(21)(22)(23)(24)(25). In most of these studies, which have attempted to investigate the incidence of neuropsychiatric symptoms among COVID-19 survivors, individuals with pre-existing psychiatric problems were excluded (specific criteria vary within each study design).…”

Section: New-onset Neuropsychiatric Sequelae In Covid-19 Survivorsmentioning

confidence: 99%

“…With respect to admission to hospital, hospitalized patients with COVID-19 compared with those treated as outpatients demonstrated higher incidences of depressive episodes (6.6 vs. 1.2%; P<0.001), panic disorder (0.3 vs. 0.1%; P<0.001), generalized anxiety (0.7 vs. 0.3%; P<0.001), PTSD (1.4 vs. 0.5%; P<0.001) and adjustment disorder (2.4 vs. 0.9%; P<0.001). Accordingly, Chen et al (23) found that among the 277 (7.9% of 3,518) veteran hospitalized COVID-19 survivors with new-onset mental health manifestations, the most common new diagnoses included depression (28%), anxiety (28%), adjustment disorders (24%) and PTSD (17%), whereas in another US veteran cohort study, Xie et al (25) ). No differences were found between the COVID-19 and the SARI cohort (reference group) regarding new-onset anxiety disorder (aHR, 1.00; 95% CI, 0.79-1.27), depression (aHR, 0.63; 95% CI, 0.25-1.58) or bipolar affective disorder (aHR, 0.74; 95% CI, 0.32-1.69).…”

Section: New-onset Affective and Anxiety Symptoms And 'Long-covid'mentioning

confidence: 99%

“…Another study in veteran patients (n=3,518), who were all hospitalized for COVID-19, between March and August 2020, revealed that 277 (7.9%) patients developed a new mental health diagnosis following hospitalization (i.e. having not been diagnosed with the specific condition within 2 years prior to hospitalization) ( 23 ). Younger patients and those residing in rural areas were more likely to develop new mental health diagnoses, whereas women and patients with more comorbidities were less likely to develop new diagnoses.…”

Section: New-onset Neuropsychiatric Sequelae In Covid-19 Survivorsmentioning

confidence: 99%

See 2 more Smart Citations

New‑onset neuropsychiatric sequelae and ‘long‑COVID’ syndrome (Review)

et al. 2022

View full text Add to dashboard Cite

The ongoing coronavirus disease 2019 (COVID-19) pandemic has had a widespread impact on individuals' mental health through indirect psychological and social mechanisms, related to factors such as fear of infection or death, social isolation, lack of social support and financial instability. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has also been associated with the development or recurrence of neuropsychiatric symptoms, both during the acute phase, as well as during the post-acute 'long-COVID' phase. In addition to the COVID-19 survivors with a mental health history that are at a high risk of experiencing a range of neuropsychiatric symptoms following resolution of acute COVID-19, there is accumulating evidence that a diagnosis of COVID-19 may also be associated with new-onset neuropsychiatric morbidity among survivors without pre-existing mental health disorders. In particular, studies investigating the incidence of post-acute neuropsychiatric sequelae, based mostly on retrospective cohort study designs and data from national health registries, have reported the development of new-onset manifestations, including depression, anxiety, psychotic symptoms, sleep disturbances and fatigue. Nevertheless, when COVID-19 survivors were compared with SARS-CoV-2-negative controls and especially survivors of other disorders (such as influenza), the findings regarding the risk of incident neuropsychiatric manifestations varied among studies. While there is evidence of an association between SARS-CoV-2 infection and the subsequent occurrence of new-onset neuropsychiatric symptoms, especially among patients with increased disease severity, further research using methodological approaches less susceptible to confounding bias is required to establish causal relationships. Contents 1. Introduction 2. New-onset neuropsychiatric sequelae in COVID-19 survivors 3. Pathophysiological mechanisms and 'long-COVID' neuropsychiatric symptoms 4. Conclusions

show abstract

Section: New-onset Neuropsychiatric Sequelae In Covid-19 Survivorsmentioning

confidence: 99%

Section: New-onset Affective and Anxiety Symptoms And 'Long-covid'mentioning

confidence: 99%

Section: New-onset Neuropsychiatric Sequelae In Covid-19 Survivorsmentioning

confidence: 99%

See 1 more Smart Citation

New‑onset neuropsychiatric sequelae and ‘long‑COVID’ syndrome (Review)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A collection of risk and protective factors have been identified to be associated with COVID‐19 1–12 . Meanwhile, COVID‐19 can give rise to a myriad of post‐COVID‐19 consequences 13–17 . Cardiovascular diseases were repeatedly identified as risk factors associated with the severity and mortality of COVID‐19 18,19 .…”

Section: Introductionmentioning

confidence: 99%

Causal associations and shared genetics between hypertension and COVID‐19

Baranova

Cao

Zhang

2023

Journal of Medical Virology

View full text Add to dashboard Cite

To evaluate the genetic relationship between hypertension and COVID-19 and explore the molecular pathways linking hypertension to COVID-19. We performed genetic correlation and Mendelian randomization (MR) analyses to assess potential associations between hypertension and hospitalized COVID-19. We compared genome-wide association signals to reveal shared genetic variation between hypertension and hospitalized COVID-19. Moreover, hypertension-driven molecular pathways were constructed based on large-scale literature data to understand the influence of hypertension on COVID-19 at the molecular level. Hypertension has a positive genetic correlation with COVID-19 (r g = 0.19). The MR analyses indicate that genetic liability to hypertension confers a causal effect on hospitalized COVID-19 (odds ratio [OR]: 1.05, confidence interval [CI]: 1.00-1.09, p = 0.030). Hypertension and hospitalized COVID-19 have three overlapping loci and share eight protein-coding risk genes, including ABO, CSF2, FUT2, IZUMO1, MAMSTR, NPNT, RASIP1, and WNT3. Molecular pathway analysis suggests that hypertension may promote the development of COVID-19 through the induction of inflammatory pathways. Our study suggests that genetically determined hypertension may increase the risk for severe COVID-19. The shared genetic variation and the connecting molecular pathways may underline causal links between hypertension and COVID-19.

show abstract

“…A collection of risk and protective factors have been identified to be associated with COVID-19 (1)(2)(3)(4)(5)(6)(7)(8)(9)(10). Meanwhile, COVID-19 can give rise to a myriad of post-COVID-19 consequences (11)(12)(13)(14)(15). The continued effectiveness of the current generation of COVID-19 vaccines and the possible acquisition of resistance to antivirals remain a concern.…”

Section: Introductionmentioning

confidence: 99%

Causal associations of tea intake with COVID-19 infection and severity

et al. 2023

View full text Add to dashboard Cite

Tea ingredients can effectively inhibit SARS-CoV-2 infection at adequate concentrations. It is not known whether tea intake could impact the susceptibility to COVID-19 or its severity. We aimed to evaluate the causal effects of tea intake on COVID-19 outcomes. We performed Mendelian randomization (MR) analyses to assess the causal associations between tea intake (N = 441,279) and three COVID-19 outcomes, including SARS-CoV-2 infection (122,616 cases and 2,475,240 controls), hospitalized COVID-19 (32,519 cases and 2,062,805 controls), and critical COVID-19 (13,769 cases and 1,072,442 controls). The MR analyses indicated that genetic propensity for tea consumption conferred a negative causal effect on the risk of SARS-CoV-2 infection (OR: 0.87, 95% confidence interval (CI): 0.78–0.97, P = 0.015). No causal effects on hospitalized COVID-19 (0.84, 0.64–1.10, P = 0.201) or critical COVID-19 (0.73, 0.51–1.03, P = 0.074) were detected. Our study revealed that tea intake could decrease the risk of SARS-CoV-2 infection, highlighting the potential preventive effect of tea consumption on COVID-19 transmission.

show abstract

Psychiatric disorders newly diagnosed among veterans subsequent to hospitalization for COVID-19

Cited by 6 publications

References 8 publications

New‑onset neuropsychiatric sequelae and ‘long‑COVID’ syndrome (Review)

New‑onset neuropsychiatric sequelae and ‘long‑COVID’ syndrome (Review)

Causal associations and shared genetics between hypertension and COVID‐19

Causal associations of tea intake with COVID-19 infection and severity

Contact Info

Product

Resources

About